M
53
16
UA
33
7
MDT
50
-2
CAH
45
-3
IP
24
2
HOG
26
-3
ZTS
29
13
FOXA
23
3
EL
39
-3
JNJ
68
-3
AIG
44
-3
AAP
26
-3
HIG
56
-8
MUR
50
-3
HST
60
3
RCL
47
-4
INTC
49
5
ADP
39
3
SIG
72
-4
SWKS
28
-11
M
53
16
UA
33
7
MDT
50
-2
CAH
45
-3
IP
24
2
HOG
26
-3
ZTS
29
13
FOXA
23
3
EL
39
-3
JNJ
68
-3
AIG
44
-3
AAP
26
-3
HIG
56
-8
MUR
50
-3
HST
60
3
RCL
47
-4
INTC
49
5
ADP
39
3
SIG
72
-4
SWKS
28
-11
Financhill
Back

Relay Therapeutics, Inc. 10K Form

Buy
70

RLAY
Relay Therapeutics, Inc.

Last Price:
$10.16
Seasonality Move:
-27.21%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive RLAY News And Ratings

See the #1 stock for the next 7 days that we like better than RLAY

RLAY Financial Statistics

Sales & Book Value

Annual Sales: $15.4M
Cash Flow: $-44.9M
Price / Cash Flow: 0
Annual Sales: $3.26
Price / Book: 3.1

Profitability

EPS (TTM): -1.61290
Net Income (TTM): $-276.5M
Gross Margin: $11.8M
Return on Equity: -41.4%
Return on Assets: -37.46%

Relay Therapeutics, Inc. Earnings Forecast

Key Relay Therapeutics, Inc. Financial Ratios

  • The Gross Profit Margin over the past 8 years for RLAY is 76.83%.
  • The Selling, General & Administrative Expenses for RLAY have been equal to 369.33% of Gross Profit Margin.
  • The Research & Development expenses have been 1,702.27% of Revenue.
  • The Net Earning history of RLAY is -1,800.58% of Total Revenues.
  • Per Share Earnings over the last 8 years have been positive in 3 years.

Relay Therapeutics, Inc. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: RLAY
CUSIP: 75943R
Website: relaytx.com

Debt

Debt-to-Equity Ratio: 0.06
Current Ratio: 22.61
Quick Ratio: 21.68

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

RLAY Technical Analysis vs Fundamental Analysis

Buy
70
Relay Therapeutics, Inc. (RLAY) is a Buy

Is Relay Therapeutics, Inc. a Buy or a Sell?